Hippigra

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hippigra

What is Hippigra? Defining the Drug Entity and Composition

Property Description
Active ingredient Sildenafil
Form Film-coated Oral Tablet
Pharmacological class Phosphodiesterase Type 5 (PDE5) Inhibitor
General Purpose Managing vascular conditions like Erectile Dysfunction (ED)
Origin Synthetic Compound

Hippigra is a pharmaceutical preparation delivered as an oral tablet whose sole active ingredient is Sildenafil. This medication is a synthetic compound manufactured as a single-ingredient product, with the therapeutic effects stemming entirely from the chemical entity Sildenafil Citrate. The drug takes the physical form of a film-coated tablet designed for simple oral administration. This form is specifically crafted to ensure consistent delivery of the Sildenafil and is combined with necessary excipients to create the stable, ingestible structure. The precise molecular identity of Sildenafil is well-defined.


What Type of Medicine is Hippigra?

Hippigra is classified as a highly selective Phosphodiesterase Type 5 (PDE5) inhibitor, defining its specific mechanism within the body. The term PDE5 inhibitor establishes the drug's role in interfering with the natural breakdown of the chemical messenger cyclic guanosine monophosphate (cGMP) in certain tissues. This precise pharmacological classification confirms its targeted function. This targeted function distinguishes Hippigra from general vasodilator drugs, confirming its basis in specialized pharmaceutical science.


What is the General Purpose of Hippigra?

The general purpose of Hippigra is to modulate blood vessel dynamics by increasing blood flow to specific areas of the body through smooth muscle relaxation. As a selective inhibitor, its core action facilitates the relaxation of smooth muscle surrounding arteries, leading to a widening of the vessels known as vasodilation. This fundamental physiological action is employed as a standard medical treatment to address erectile dysfunction (ED) in adult males and is also utilized for managing abnormally high blood pressure in the arteries of the lungs, a condition known as pulmonary arterial hypertension (PAH). Sildenafil has an established application and utility across these vascular indications.

What side effects are possible with Hippigra?

Possible side effects and safety information

The official safety profile for Hippigra (Sildenafil) is structured by government regulatory agencies based on the frequency and system-organ class affected. The most frequently reported adverse reactions are generally related to the drug’s vasodilatory action.

Frequency-Classified Adverse Reactions

Classification Adverse Reactions
Very Common Headache, Flushing
Common Dyspepsia (indigestion), Abnormal Vision (including color tinge/cyanopsia), Nasal Congestion, Dizziness, Back Pain, Myalgia, Nausea

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight rare, but clinically significant post-marketing events, including Priapism (prolonged erection lasting more than four hours), Sudden Vision Loss (Non-arteritic anterior ischemic optic neuropathy - NAION), and Sudden Hearing Loss.

Official labeling mandates strict contraindications due to documented safety risks. Hippigra is strictly forbidden for concomitant use with any form of organic nitrates or guanylate cyclase stimulators (e.g., riociguat), as this combination risks severe, life-threatening hypotension. Furthermore, use is not recommended in patients with Pulmonary Veno-Occlusive Disease (PVOD).

Population-Specific Safety Notes

The clearance of Sildenafil is noted to be reduced in certain populations, leading to increased plasma concentrations. This applies to older adults (aged 65 years and over) and patients with severe hepatic impairment. Use in pediatric patients for Pulmonary Arterial Hypertension is not recommended due to increased mortality observed in a long-term trial. Caution is also noted for patients with conditions that predispose them to Priapism, such as sickle cell anemia or anatomical deformation of the penis.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

The information below is strictly derived from authoritative government regulatory documents, detailing the official overdose profile for Hippigra and when urgent medical attention is required.

Overdose Manifestations and Risks

Official regulatory reports indicate that an overdose, typically involving doses exceeding the maximum recommended strength, may result in an increased incidence and severity of expected adverse events. Documented signs and symptoms in cases of increased exposure include hypotension (low blood pressure), dizziness, flushing, headache, and visual disturbances. The primary physiological systems affected are the cardiovascular and central nervous systems.

Life-threatening risks are associated with persistent, symptomatic reactions. The most critical, label-derived complication is priapism (a prolonged erection that lasts longer than four hours).

Emergency Actions and Management

Immediate medical help is required if you experience an erection lasting more than four hours or any signs of severe symptomatic hypotension (e.g., fainting, severe dizziness). You should contact a poison control center or seek emergency medical services immediately in these situations or if a suspected overdose has occurred.

The official management protocol for an overdose involves standard supportive measures to address symptoms, as no specific antidote for Hippigra is identified in regulatory documentation. Due to the drug’s high plasma protein binding and large volume of distribution, procedures such as renal dialysis are not expected to accelerate the clearance of the drug from the body significantly.

Therapeutic Uses of Hippigra

Hippigra contains sildenafil, and its primary clinical focus may assist with managing conditions involving episodic or fluctuating manifestations that affect functional stability. The medication is commonly used to help with two conditions: erectile dysfunction (ED) and pulmonary arterial hypertension (PAH).

This medicine is considered relevant for easing symptoms that interfere with daily functioning in adult men with ED. It is also applied in addressing the heightened systemic burden associated with PAH, a condition marked by increased physiological stress.

This supportive care contributes to improved comfort during periods of heightened symptoms and helps maintain a sense of stability when symptoms are more noticeable.

“This application may provide support that helps ease the overall symptom burden for patients during difficult episodes by easing distress.”


Quick Fact: Relief for Symptoms Related to Heightened Physiological Activity


Regulatory References

  1. NIH MedlinePlus overview of Sildenafil

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Hippigra — official regulatory information

Eligibility scope

Classification Population Status
Populations for whom use is allowed Adult men; Adult PAH patients; Pediatric PAH patients (aged 1–17) Eligible
Populations for whom use is not recommended Patients with Pulmonary Veno-Occlusive Disease (PVOD); Pulmonary Hypertension secondary to Sickle Cell Disease; Retinitis Pigmentosa Restricted
Populations for whom use is contraindicated Patients using organic nitrates or sGC stimulators; Known hypersensitivity; Recent stroke or myocardial infarction; Severe hypotension ( BP < 90/50 mmHg); History of NAION-related vision loss Prohibited

Age-related eligibility rules: Adults (18 years) are the primary eligible group. Pediatric patients under 1 year of age are a use-not-established group. Older adults (65 years) are eligible but are often noted in labeling as requiring cautious consideration due to reduced drug clearance.

Condition-specific eligibility rules: Use is strictly limited in patients with severe hepatic impairment (contraindicated in some jurisdictions). Patients with severe renal impairment and those taking alpha-blockers are restricted populations, requiring cautious initiation.

Pregnancy and lactation eligibility status (if explicitly documented): Hippigra is not indicated for women for the ED use. For PAH, use during pregnancy is permitted as a conditional risk-benefit decision. Data on excretion into human milk during lactation is insufficient to fully establish risk.


Official eligibility statements:

  • The medicine is contraindicated with all forms of nitrates and sGC stimulators.
  • Use is contraindicated in patients with recent stroke or myocardial infarction and those with severe hypotension.
  • The safety has not been established in pediatric patients younger than 1 year of age.

Connection to the overall eligibility profile: Official regulatory documents strictly define who can and cannot use Hippigra by establishing absolute contraindications (e.g., concomitant nitrate use) and delineating restricted or conditional use populations based on specific criteria, including organ function status and age-group limitations, thereby setting clear, official boundaries for the patient population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hippigra (sildenafil) carries a major interaction risk with certain medicinal products, primarily due to potentiation of its blood pressure-lowering effects and through metabolic interference.

Contraindicated Combinations

Co-administration with nitrates (organic nitrates or organic nitrites/nitric oxide donors, such as nitroglycerin or isosorbide dinitrate) in any form (regular or intermittent use) is strictly contraindicated. This combination results in a severe, potentially life-threatening drop in blood pressure.

Other Clinically Significant Interactions

Interaction Mechanism Interacting Product Categories Regulatory Constraint/Action
Potentiation of Hypotensive Effects Alpha-blockers (e.g., doxazosin, tamsulosin) and Anti-hypertensives (e.g., amlodipine) Caution is advised. Patients must be stable on alpha-blocker therapy before starting Hippigra, which should be initiated at a lower dose (25 mg). Additive blood pressure-lowering effects may occur.
Inhibition of Metabolism (Increased Exposure) Strong CYP3A Inhibitors (e.g., ritonavir, ketoconazole, itraconazole) Caution and dose reduction are required. For example, when co-administered with ritonavir, a maximum single dose of 25 mg over a 48-hour period is recommended.
Induction of Metabolism (Decreased Exposure) CYP Inducers (e.g., bosentan) May cause decreased blood plasma concentrations of Hippigra, potentially requiring a dose increase.

Food/Beverage Interaction: High-fat meals can delay the rate of absorption of Hippigra, meaning the onset of effect may be slower than if the drug were taken on an empty stomach.

Mechanism of Action

The mechanism of Hippigra, which contains Sildenafil, is entirely pharmacodynamic, focusing on the inhibition of a key regulatory enzyme within the vascular system. The core mechanism is centered on the selective competitive inhibition of the Phosphodiesterase Type 5 ( PDE5) enzyme. This enzyme is the primary biological target, responsible for the breakdown of the crucial intracellular messenger cyclic Guanosine Monophosphate ( cGMP). By binding to PDE5, the drug prevents this hydrolysis, thereby sustaining the effective intracellular concentration of cGMP. This inhibitory action enhances the effectiveness of the body's natural Nitric Oxide ( NO)-cGMP signaling pathway. The sustained high levels of cGMP activate a downstream cascade that leads directly to a reduction in the contractile state of smooth muscle. The resulting physiological effect is the relaxation of vascular smooth muscle and subsequent localized vasodilation (widening of blood vessels) in areas where the PDE5 enzyme is highly expressed. This mechanism is entirely dependent on the prior release of NO within the tissue, and the resulting localized vasodilation enhances local blood perfusion only when the natural signaling cue is present.

Dosage and Administration Information

Hippigra, which contains the active ingredient sildenafil, is administered through two distinct protocols dictated by its specific purpose. The administration route is primarily oral via film-coated tablets for both usage patterns, although an intravenous (IV) bolus injection is an approved alternative for the Pulmonary Arterial Hypertension (PAH) indication when the oral route is temporarily infeasible.

Usage for Erectile Dysfunction (ED)

The usage for the ED indication is characterized by an as-needed frequency, with a standard starting dose of 50 mg. This single dose is taken approximately one hour before planned activity, but the administration window extends from 30 minutes up to four hours prior. The maximum recommended frequency is once per day, and the dose may be adjusted between 25 mg and 100 mg based on individual factors. The drug’s action for ED is dependent upon concomitant sexual stimulation. A lower starting dose of 25 mg is typically used for older adults (65 years and older) and for patients with severe kidney or liver impairment.

Usage for Pulmonary Arterial Hypertension (PAH)

For the PAH indication, the regimen involves a scheduled maintenance pattern. The standard oral dose is 20 mg, taken three times a day (TID), with the doses spaced approximately four to six hours apart. This dosage may be titrated (adjusted) up to a maximum of 80 mg TID. This regimen is considered continuous, long-term use. The drug may be taken with or without food for both usage patterns; however, consuming it with a high-fat meal is known to delay the time until the drug begins its action. If a scheduled PAH dose is missed, the standard procedure is to take the dose as soon as possible and resume the normal schedule, avoiding a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Hippigra

Evidence for use in Erectile Dysfunction (ED) in Adult Males

Research related to Hippigra in adult men with Erectile Dysfunction (ED) was studied in numerous large Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). These short-term studies were followed by longer-term Open-Label Extension Studies used in research exploring how symptoms change over time. Studies explored outcomes related to daily functioning, specifically using validated questionnaires, such as the International Index of Erectile Function (IIEF), to track patient-reported outcomes describing perceived discomfort.

Studies reported patterns observed in the trials comparing the active ingredient to an inactive placebo. Research describes changes measured during the study period concerning patients' ability to attain and maintain an erection, and reports on the success rates of sexual attempts, based on event logs.


Evidence for use in Pulmonary Arterial Hypertension (PAH) in Adults

Hippigra was evaluated in research exploring conditions characterized by functional limitations, specifically Pulmonary Arterial Hypertension (PAH). The foundational research includes Randomized, Double-Blind, Placebo-Controlled Trials (RCTs) which explored outcomes reflecting daily functioning and physiological strain. Studies monitored changes in exercise capacity, which was studied for using the 6-minute walk distance (6MWD). Trials also monitored a composite outcome called the time to clinical worsening.


What is Still Uncertain About the Research for Hippigra

Long-term outcomes are not fully established based only on the initial short-term RCTs. The follow-up durations were limited in the pivotal controlled trials, meaning the full scope of very long-term outcomes is primarily informed by observational data.

Specific regulatory bodies have documented differing conclusions regarding data for long-term use in the pediatric PAH population, indicating that data for certain groups remain insufficient. Furthermore, the initial research for PAH was not powered to show differences in endpoints like all-cause mortality, meaning that in this specific area, certainty remains low.

Key Studies & References Sildenafil (Oral Route) - NIH MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Hippigra (FAQ)


Q: What are the most common side effects people report with Hippigra?

A: According to official regulatory documents, the most common side effects reported with Hippigra are generally linked to its action of widening blood vessels. Very common reactions include headache and flushing. Other common effects can involve upset stomach (dyspepsia), nasal congestion, and changes in vision, such as a color tinge.

Q: Is it true that Hippigra can interact with grapefruit juice?

A: Grapefruit and grapefruit juice are known to affect the body’s ability to break down certain medications, including Hippigra. This is because Hippigra is metabolized by an enzyme called CYP3A. Consuming grapefruit can increase the amount of the drug in your system. The interaction potential highlights the importance of discussing all foods, beverages, and supplements with a healthcare provider.

Q: What happens if I forget to take Hippigra?

A: If Hippigra is being taken as a scheduled, continuous treatment for Pulmonary Arterial Hypertension (PAH), the guidance for a missed dose instructs the patient to take the dose as soon as it is remembered and then resume the normal schedule, avoiding a double dose. For the Erectile Dysfunction (ED) indication, which is taken only as needed, a forgotten dose is not applicable.

Q: What are the signs of an allergic reaction to Hippigra?

A: Official labeling states that Hippigra is strictly forbidden for use if a patient has a known hypersensitivity to the active ingredient or any components of the tablet. The patient information leaflet typically describes the need to seek immediate medical attention if you suspect signs of a serious allergic reaction, which can include swelling of the face or difficulty breathing.

Q: Can Hippigra be crushed or split?

A: Hippigra is manufactured as a film-coated tablet for oral administration. Unless specific instructions for modification are provided by the manufacturer or prescriber, film-coated tablets are generally intended to be swallowed whole to maintain stability and consistent drug delivery.

Q: Why is proper timing important when taking Hippigra?

A: Proper timing is important because it ensures the drug is available in your body when needed, and its effectiveness can be influenced by food. For 'as-needed' use, it is typically taken about one hour before activity. Taking it with a high-fat meal can slow down how quickly the drug starts to work.

Q: What are the main warnings listed on the Hippigra patient leaflet?

A: Key warnings in the patient leaflet include a strict prohibition against using Hippigra with any form of organic nitrates or specific other drugs (sGC stimulators), due to the risk of a dangerous drop in blood pressure. Official warnings also highlight rare but serious events such as a prolonged erection (priapism), sudden vision loss, and sudden hearing loss.

Q: Is it normal for the effect of Hippigra to be less noticeable over time?

A: Regulatory information indicates that the initial pivotal controlled trials for the drug were conducted over a short period. Official documents do not explicitly state that the effect diminishes over time. Any perceived change in the medication's effectiveness is a topic that should be reviewed with a healthcare provider for re-evaluation.

Q: Is Hippigra the same kind of drug as [Similar Drug Name]?

A: Hippigra is part of a class of medications known as selective Phosphodiesterase Type 5 (PDE5) inhibitors. While other medicines may belong to the same pharmacological class, they contain different active ingredients. These differences mean that the onset, duration, and specific side effect profile may vary among products in the class.

Q: Does Hippigra work for women too?

A: The official product information states that Hippigra is not indicated for women for the treatment of Erectile Dysfunction (ED). However, it is used by both men and women for the treatment of Pulmonary Arterial Hypertension (PAH). For the PAH indication, use during pregnancy is assessed based on a conditional risk-benefit determination documented in the official labeling.

Q: Is Hippigra considered an old or new treatment option?

A: The active ingredient in Hippigra, sildenafil, was among the first in its pharmacological class to receive regulatory approval. This means it is an established treatment option with extensive regulatory review and a well-documented history of use.

Q: What's the difference between Hippigra and the generic version?

A: Hippigra is the brand-name product containing the active ingredient sildenafil. The generic version contains the exact same active ingredient. Generic products are required by regulatory agencies to be bioequivalent, meaning they work the same way and provide the same clinical benefit as the brand-name drug.

Q: What if I'm taking herbal supplements—do they interact with Hippigra?

A: Official regulatory documents list known interactions with prescription medications, such as strong CYP3A inhibitors. Regulatory agencies emphasize the importance of informing a healthcare provider about all products used, including herbal supplements, to properly evaluate potential drug-herb interactions.

Q: Can I drink alcohol while I am using Hippigra?

A: Official regulatory documents do not state a strict prohibition against consuming alcohol while taking Hippigra. Caution is noted because alcohol can independently lower blood pressure and may increase the risk of experiencing side effects such as dizziness or headache.

Q: Does Hippigra cure the underlying problem or just treat symptoms?

A: Hippigra is a symptomatic treatment. Its action is to temporarily relax smooth muscle and increase blood flow, which addresses symptoms but does not treat or cure the underlying medical conditions, such as the cause of Erectile Dysfunction or Pulmonary Arterial Hypertension.

Q: What are the serious but rare side effects of Hippigra?

A: Regulatory documents highlight certain rare events that are considered clinically significant. These serious adverse reactions include prolonged erection (priapism), sudden loss of vision (NAION), and sudden loss of hearing.

Q: Is there a maximum amount of time Hippigra can be taken safely?

A: For the treatment of Pulmonary Arterial Hypertension (PAH), Hippigra is prescribed as a scheduled, continuous, long-term use regimen. Any duration of use is determined by the prescriber based on the individual patient’s condition and ongoing assessment.

Q: Is Hippigra available over-the-counter in some countries?

A: Hippigra is a prescription-only medicine in many major regions. However, in some jurisdictions, regulatory bodies have approved the active ingredient, sildenafil, for over-the-counter availability in specific formulations and restricted dosages.

Q: Can teenagers be prescribed Hippigra?

A: The active ingredient in Hippigra is approved for use in pediatric patients (ages 1 to 17) only for the treatment of Pulmonary Arterial Hypertension (PAH). The use of Hippigra for the treatment of Erectile Dysfunction is not established for this age group.

Q: Does Hippigra have any impact on mood or sleep?

A: Official regulatory safety data tracks effects on the nervous system. Dizziness is listed as a common adverse reaction, but effects on mood or sleep are not typically listed as common side effects in the official product information.

Q: Is Hippigra tested on animals?

A: As with most prescription drugs, the regulatory submission for Hippigra includes a 'Preclinical Safety Data' section. This section summarizes data obtained from animal studies that were required to establish the drug's safety profile before it could be tested in human clinical trials.

Q: Where can I find reliable, unbiased information about Hippigra?

A: Reliable and unbiased information can be found in official documents published by government agencies. This includes the FDA Prescribing Information, the EMA Summary of Product Characteristics (SmPC), or patient-focused educational resources such as the NIH’s MedlinePlus.

How should Hippigra be stored and disposed of?

How to Store and Dispose of Hippigra?

Official regulatory requirements define specific rules for storing and disposing of Hippigra to maintain its stability and prevent misuse.

Storage Requirements

Hippigra must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, tightly closed, and protected from excess heat, moisture, and light. It is essential to keep the medication out of the sight and reach of children in a secure location. If Hippigra is prepared as a compounded capsule formulation, the official Beyond-Use Date may be 6 months.

Disposal Requirements

Unused or expired Hippigra should be disposed of promptly and safely. The most recommended method is to use a drug take-back program or mail-back envelope. If these options are not readily available, the medication may be mixed with an undesirable substance (such as dirt or coffee grounds), placed into a sealed bag or container, and discarded with household trash. Do not flush the medication down the toilet unless specific instructions for flushing are provided on the regulatory labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hippigra found in:

A-Z Index: